Trial Information

Summary: A Phase I Study of the HSP90 Inhibitor STA-9090 in Patients with Solid Tumors

The purpose of this study is to determine the safety and tolerability of STA-9090 when administered in patients with solid tumors. The study will assess the effects of the drug on patients and their cancers and analyze the pharmacokinetics of STA-9090. Pharmacokinetics (PKs) is a way to determine the level of drug in the patient's blood and to study how the body processes the drug by looking at how the drug is absorbed, distributed, metabolized and eliminated. This is done by frequent blood draws on key days during the first four weeks of treatment.

STA-9090 is a synthetic small molecule targeted therapy and is an inhibitor of heat shock protein 90 (HSP90). HSP90 belongs to a class of molecular chaperone proteins that are involved in the proliferation and survival of cancer cells. STA-9090 is not approved by the FDA and is considered investigational in this study.

Patient Inclusion Criteria:

• Patients > 25 years old
• Adequate liver, kidney and bone marrow function
• Stable brain mets
• Anticoagulation OK

Not all eligibility criteria are listed. Additional criteria must be met in order to be eligible.

Patient Exclusion Criteria:

• Previous radiation therapy to > 25% of the bone marrow
• Bone marrow transplant
• Left ventricular ejection fraction < 45%

If you would like to learn more about participating in this study, please send an e-mail message using the form below.